Trial reportCanadian journal of gastroenterology = Journal canadien de gastroenterologie2013
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.
Trial report in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 69 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 6 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Unraveling immunological heterogeneity in recalcitrant AIH-PBC/PSC overlap syndromes: from molecular crosstalk to precision therapeutics.Frontiers in immunology · 2026Pooled it
- Autoimmune hepatitis in children: Guidelines of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN).Hepatology international · 2025Guideline
- British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis.Gut · 2025Guideline
- KASL clinical practice guidelines for management of autoimmune hepatitis 2022.Clinical and molecular hepatology · 2023Guideline
- Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.Frontiers in immunology · 2019Pooled it
- Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.World journal of gastroenterology · 2017Pooled it
- Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series.Gastro hep advances · 2026Article
- Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review.Frontiers in pharmacology · 2026Review
- Management of refractory autoimmune hepatitis with rituximab: a case series.Journal of medical case reports · 2025Article
- Difficult to treat and refractory autoimmune hepatitis: Recent advances in pharmacological management.World journal of hepatology · 2025Review
- The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2025Review
- Evaluation of biological therapies in autoimmune hepatitis: A case-based systematic review.World journal of gastrointestinal pathophysiology · 2025Article
- Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis.The Journal of clinical investigation · 2025Article
- Autoimmune hepatitis: Towards a personalized treatment.World journal of hepatology · 2024Review
- B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes.JPGN reports · 2024Article
- Role of Sirolimus and Rituximab in the Treatment of Autoimmune Hepatitis.ACG case reports journal · 2024Article
- Multiple autoimmune disorders refractory to glucocorticoids after allogeneic hematopoietic stem cell transplantation: a case report and review of the literature.Frontiers in immunology · 2024Review
- Review
- Seronegative Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2023Review
- [Treatment of Autoimmune Hepatitis].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedSantodomino-Garzon, Tania [corrected to Santodomingo-Garzon, Tania]
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and⁄or azathioprine, some patients are intolerant or refractory to standard therapy. Rituximab is an anti-CD20 monoclonal antibody that depletes B cells and has demonstrated efficacy in other autoimmune conditions.
aimsTo evaluate the safety and efficacy of rituximab in patients with refractory AIH in an open-label, single-centre pilot study.
methodsSix patients with definite, biopsy-proven AIH who failed prednisone and azathioprine treatment received two infusions of rituximab 1000 mg two weeks apart and were followed for 72 weeks.
resultsRituximab was well tolerated with no serious adverse events. By week 24, mean (± SD) aspartate aminotransferase (AST) levels had significantly improved (90.0±23.3 U⁄L versus 31.3±4.2 U⁄L; P=0.03) and mean immunoglobulin G levels had fallen (16.4±2.0 g⁄L versus 11.5±1.1 g⁄L; P=0.056). The prednisone dose was weaned in three of four subjects, with one subject flaring after steroid withdrawal. Inflammation grade improved in all four subjects who underwent repeat liver biopsy at week 48. Regulatory T cell levels examined by FoxP3 immunohistochemistry paralleled inflammatory activity and did not increase on follow-up biopsies. There was no significant change in serum chemokine or cytokine levels from baseline to week 24 (n=5), although interferon-gamma-induced protein 10 levels improved in three of five subjects.
conclusionsRituximab was safe, well tolerated and resulted in biochemical improvement in subjects with refractory AIH. These results support further investigation of rituximab as a treatment for AIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.